Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells
Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the...
Gespeichert in:
Veröffentlicht in: | The Journal of pharmacology and experimental therapeutics 2010-12, Vol.335 (3), p.562-571 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 571 |
---|---|
container_issue | 3 |
container_start_page | 562 |
container_title | The Journal of pharmacology and experimental therapeutics |
container_volume | 335 |
creator | Li, Linhao Hassan, Hazem E. Tolson, Antonia H. Ferguson, Stephen S. Eddington, Natalie D. Wang, Hongbing |
description | Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation. |
doi_str_mv | 10.1124/jpet.110.173187 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524461235</els_id><sourcerecordid>20829393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</originalsourceid><addsrcrecordid>eNp1kc9uEzEQxi0EomnhzA35BZb6z3q7viCFlDZIlYqqInGzJt5x62pjr2wnUh6DN8ZpIIJDT55P8_lnz3yEfODsE-eiPX-asNSqqgvJ-4tXZMaV4A3jTL4mM8aEaKTq1Ak5zfmJMd62nXxLTgTrhZZazsivS-8cJgzFw0jntvgtFB8DjY5-T_gQICD9Se_Q4lRiohAGuoghF1821Yt0HoYUc9nbjqbVjn7ZTBUa0_Toa8eHCvNrSDu63Kwh0CVOUKLdFczPyKqvBV3gOOZ35I2DMeP7P-cZ-XH19X6xbG5ur78t5jeNVVKWxiLolWKKg5O6Dm_FwF3fD53kgK5VnVYc265nnQOEdsCuik6DdQ5WvUZ5Rj4fuNNmtcbB1hUkGM10-KeJ4M3_neAfzUPcGqG1VEpVwPkBYOsCckJ3vMuZ2adj9unUqqrndOqNj_8-efT_jaMa9MGAdfCtx2Sy9RgsDj6hLWaI_kX4bzR7o8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</creator><creatorcontrib>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</creatorcontrib><description>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.110.173187</identifier><identifier>PMID: 20829393</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Active Transport, Cell Nucleus - drug effects ; Active Transport, Cell Nucleus - physiology ; Analgesics, Opioid - metabolism ; Aryl Hydrocarbon Hydroxylases - genetics ; Aryl Hydrocarbon Hydroxylases - metabolism ; Buprenorphine - metabolism ; Buprenorphine - pharmacology ; Cytochrome P-450 CYP2B6 ; Cytochrome P-450 CYP3A - genetics ; Cytochrome P-450 CYP3A - metabolism ; Diprenorphine - metabolism ; Diprenorphine - pharmacology ; Gene Expression - drug effects ; Gene Expression - genetics ; Genes, Reporter - genetics ; Hep G2 Cells ; Hepatocytes - drug effects ; Hepatocytes - metabolism ; Humans ; Metabolism, Transport, and Pharmacogenomics ; Oxidoreductases, N-Demethylating - genetics ; Oxidoreductases, N-Demethylating - metabolism ; Pregnane X Receptor ; Receptors, Cytoplasmic and Nuclear - agonists ; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors ; Receptors, Cytoplasmic and Nuclear - genetics ; Receptors, Cytoplasmic and Nuclear - metabolism ; Receptors, Steroid - agonists ; Receptors, Steroid - antagonists & inhibitors ; Receptors, Steroid - genetics ; Receptors, Steroid - metabolism ; Transfection</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2010-12, Vol.335 (3), p.562-571</ispartof><rights>2010 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</citedby><cites>FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20829393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Linhao</creatorcontrib><creatorcontrib>Hassan, Hazem E.</creatorcontrib><creatorcontrib>Tolson, Antonia H.</creatorcontrib><creatorcontrib>Ferguson, Stephen S.</creatorcontrib><creatorcontrib>Eddington, Natalie D.</creatorcontrib><creatorcontrib>Wang, Hongbing</creatorcontrib><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</description><subject>Active Transport, Cell Nucleus - drug effects</subject><subject>Active Transport, Cell Nucleus - physiology</subject><subject>Analgesics, Opioid - metabolism</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Buprenorphine - metabolism</subject><subject>Buprenorphine - pharmacology</subject><subject>Cytochrome P-450 CYP2B6</subject><subject>Cytochrome P-450 CYP3A - genetics</subject><subject>Cytochrome P-450 CYP3A - metabolism</subject><subject>Diprenorphine - metabolism</subject><subject>Diprenorphine - pharmacology</subject><subject>Gene Expression - drug effects</subject><subject>Gene Expression - genetics</subject><subject>Genes, Reporter - genetics</subject><subject>Hep G2 Cells</subject><subject>Hepatocytes - drug effects</subject><subject>Hepatocytes - metabolism</subject><subject>Humans</subject><subject>Metabolism, Transport, and Pharmacogenomics</subject><subject>Oxidoreductases, N-Demethylating - genetics</subject><subject>Oxidoreductases, N-Demethylating - metabolism</subject><subject>Pregnane X Receptor</subject><subject>Receptors, Cytoplasmic and Nuclear - agonists</subject><subject>Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors</subject><subject>Receptors, Cytoplasmic and Nuclear - genetics</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Receptors, Steroid - agonists</subject><subject>Receptors, Steroid - antagonists & inhibitors</subject><subject>Receptors, Steroid - genetics</subject><subject>Receptors, Steroid - metabolism</subject><subject>Transfection</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQxi0EomnhzA35BZb6z3q7viCFlDZIlYqqInGzJt5x62pjr2wnUh6DN8ZpIIJDT55P8_lnz3yEfODsE-eiPX-asNSqqgvJ-4tXZMaV4A3jTL4mM8aEaKTq1Ak5zfmJMd62nXxLTgTrhZZazsivS-8cJgzFw0jntvgtFB8DjY5-T_gQICD9Se_Q4lRiohAGuoghF1821Yt0HoYUc9nbjqbVjn7ZTBUa0_Toa8eHCvNrSDu63Kwh0CVOUKLdFczPyKqvBV3gOOZ35I2DMeP7P-cZ-XH19X6xbG5ur78t5jeNVVKWxiLolWKKg5O6Dm_FwF3fD53kgK5VnVYc265nnQOEdsCuik6DdQ5WvUZ5Rj4fuNNmtcbB1hUkGM10-KeJ4M3_neAfzUPcGqG1VEpVwPkBYOsCckJ3vMuZ2adj9unUqqrndOqNj_8-efT_jaMa9MGAdfCtx2Sy9RgsDj6hLWaI_kX4bzR7o8I</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Li, Linhao</creator><creator>Hassan, Hazem E.</creator><creator>Tolson, Antonia H.</creator><creator>Ferguson, Stephen S.</creator><creator>Eddington, Natalie D.</creator><creator>Wang, Hongbing</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20101201</creationdate><title>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</title><author>Li, Linhao ; Hassan, Hazem E. ; Tolson, Antonia H. ; Ferguson, Stephen S. ; Eddington, Natalie D. ; Wang, Hongbing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-cea9b5051af39731c2d1f88d631aef456951e46806faea4de646869acffab89e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Active Transport, Cell Nucleus - drug effects</topic><topic>Active Transport, Cell Nucleus - physiology</topic><topic>Analgesics, Opioid - metabolism</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Buprenorphine - metabolism</topic><topic>Buprenorphine - pharmacology</topic><topic>Cytochrome P-450 CYP2B6</topic><topic>Cytochrome P-450 CYP3A - genetics</topic><topic>Cytochrome P-450 CYP3A - metabolism</topic><topic>Diprenorphine - metabolism</topic><topic>Diprenorphine - pharmacology</topic><topic>Gene Expression - drug effects</topic><topic>Gene Expression - genetics</topic><topic>Genes, Reporter - genetics</topic><topic>Hep G2 Cells</topic><topic>Hepatocytes - drug effects</topic><topic>Hepatocytes - metabolism</topic><topic>Humans</topic><topic>Metabolism, Transport, and Pharmacogenomics</topic><topic>Oxidoreductases, N-Demethylating - genetics</topic><topic>Oxidoreductases, N-Demethylating - metabolism</topic><topic>Pregnane X Receptor</topic><topic>Receptors, Cytoplasmic and Nuclear - agonists</topic><topic>Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors</topic><topic>Receptors, Cytoplasmic and Nuclear - genetics</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Receptors, Steroid - agonists</topic><topic>Receptors, Steroid - antagonists & inhibitors</topic><topic>Receptors, Steroid - genetics</topic><topic>Receptors, Steroid - metabolism</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Linhao</creatorcontrib><creatorcontrib>Hassan, Hazem E.</creatorcontrib><creatorcontrib>Tolson, Antonia H.</creatorcontrib><creatorcontrib>Ferguson, Stephen S.</creatorcontrib><creatorcontrib>Eddington, Natalie D.</creatorcontrib><creatorcontrib>Wang, Hongbing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Linhao</au><au>Hassan, Hazem E.</au><au>Tolson, Antonia H.</au><au>Ferguson, Stephen S.</au><au>Eddington, Natalie D.</au><au>Wang, Hongbing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>335</volume><issue>3</issue><spage>562</spage><epage>571</epage><pages>562-571</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>Buprenorphine is a partial μ-opioid receptor agonist used for the treatment of opioid dependence that has several advantages over methadone. The principal route of buprenorphine disposition has been well established; however, little is known regarding the potential for buprenorphine to influence the metabolism and clearance of other drugs by affecting the expression of drug-metabolizing enzymes (DMEs). Here, we investigate the effects of buprenorphine on the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as the induction of DMEs, in both HepG2 cells and human primary hepatocytes (HPHs). In HepG2 cells, buprenorphine significantly increased human PXR-mediated CYP2B6 and CYP3A4 reporter activities. CYP2B6 reporter activity was also enhanced by buprenorphine in HepG2 cells cotransfected with a chemical-responsive human CAR variant. Real-time reverse transcription-polymerase chain reaction analysis revealed that buprenorphine strongly induced CYP3A4 expression in both PXR- and CAR-transfected HepG2 cells. However, treatment with the same concentrations of buprenorphine in HPHs resulted in literally no induction of CYP3A4 or CYP2B6 expression. Further studies indicated that buprenorphine could neither translocate human CAR to the nucleus nor activate CYP2B6/CYP3A4 reporter activities in transfected HPHs. Subsequent experiments to determine whether the differential response was due to buprenorphine’s metabolic stability revealed a dramatically differential rate of elimination for buprenorphine between HPHs and HepG2 cells. Taken together, these studies indicate that metabolic stability of buprenorphine defines the differential induction of DMEs observed in HepG2 and HPHs, and the results obtained from PXR and CAR reporter assays in immortalized cell line require cautious interpretation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20829393</pmid><doi>10.1124/jpet.110.173187</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3565 |
ispartof | The Journal of pharmacology and experimental therapeutics, 2010-12, Vol.335 (3), p.562-571 |
issn | 0022-3565 1521-0103 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993555 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Active Transport, Cell Nucleus - drug effects Active Transport, Cell Nucleus - physiology Analgesics, Opioid - metabolism Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Buprenorphine - metabolism Buprenorphine - pharmacology Cytochrome P-450 CYP2B6 Cytochrome P-450 CYP3A - genetics Cytochrome P-450 CYP3A - metabolism Diprenorphine - metabolism Diprenorphine - pharmacology Gene Expression - drug effects Gene Expression - genetics Genes, Reporter - genetics Hep G2 Cells Hepatocytes - drug effects Hepatocytes - metabolism Humans Metabolism, Transport, and Pharmacogenomics Oxidoreductases, N-Demethylating - genetics Oxidoreductases, N-Demethylating - metabolism Pregnane X Receptor Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors Receptors, Cytoplasmic and Nuclear - genetics Receptors, Cytoplasmic and Nuclear - metabolism Receptors, Steroid - agonists Receptors, Steroid - antagonists & inhibitors Receptors, Steroid - genetics Receptors, Steroid - metabolism Transfection |
title | Differential Activation of Pregnane X Receptor and Constitutive Androstane Receptor by Buprenorphine in Primary Human Hepatocytes and HepG2 Cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A55%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20Activation%20of%20Pregnane%20X%20Receptor%20and%20Constitutive%20Androstane%20Receptor%20by%20Buprenorphine%20in%20Primary%20Human%20Hepatocytes%20and%20HepG2%20Cells&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Li,%20Linhao&rft.date=2010-12-01&rft.volume=335&rft.issue=3&rft.spage=562&rft.epage=571&rft.pages=562-571&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.110.173187&rft_dat=%3Cpubmed_cross%3E20829393%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20829393&rft_els_id=S0022356524461235&rfr_iscdi=true |